Patents Assigned to Pfizer
  • Method of producing 4-1BB binding molecules and associated nucleic acids
    Patent number: 9468678
    Abstract: The present disclosure provides isolated binding molecules that bind to human 4-1BB, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions.
    Type: Grant
    Filed: May 13, 2014
    Date of Patent: October 18, 2016
    Assignee: Pfizer Inc.
    Inventors: Bianca Ahrens, Sangita M. Baxi, Timothy Scott Fisher, Richard Michael Jerome, Kathrin Ladetzki-Baehs, Theodore Oliphant, Leslie Lynne Sharp, Michael Tesar, Libbey Anne Yates, Moritz Zulley
  • Prostate-associated antigens and vaccine-based immunotherapy regimens
    Patent number: 9468672
    Abstract: The present disclosure provides (a) isolated immunogenic PAA polypeptides; (b) isolated nucleic acid molecules encoding immunogenic PAA polypeptides; (c) vaccine compositions comprising an immunogenic PAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic PAA polypeptide; (d) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions; and (e) vaccine-based immunotherapy regimens which involve co-administration of a vaccine in combination with an immune-suppressive-cell inhibitor and an immune-effector-cell enhancer.
    Type: Grant
    Filed: March 13, 2015
    Date of Patent: October 18, 2016
    Assignee: Pfizer Inc.
    Inventors: Joseph John Binder, Helen Kim Cho, Michael Robert Dermyer, Karin Ute Jooss, Brian Gregory Pierce, Joyce Tsi Tan, Van To Tsai
  • THERAPEUTIC ANTIBODIES AND THEIR USES
    Publication number: 20160297885
    Abstract: The present invention relates to antibodies, e.g., full length antibodies or antigen binding fragments thereof, that specifically bind to BCMA (B-Cell Maturation Antigen) and/or CD3 (Cluster of Differentiation 3). The invention also relates to antibody conjugates (e.g., antibody-drug-conjugates) comprising the BCMA antibodies, compositions comprising the BCMA antibodies, and methods of using the BCMA antibodies and their conjugates for treating conditions associated with cells expressing BCMA (e.g., cancer or autoimmune disease). The invention further relates to heteromultimeric antibodies that specifically bind to CD3 and a tumor cell antigen, (e.g., bispecific antibodies that specifically bind to CD3 and BCMA). Compositions comprising such heteromultimeric antibodies, methods for producing and purifying such heterodimeric antibodies, and their use in diagnostics and therapeutics are also provided.
    Type: Application
    Filed: March 30, 2016
    Publication date: October 13, 2016
    Applicant: PFIZER INC.
    Inventors: Tracy Chia-Chien KUO, Javier Fernando CHAPARRO RIGGERS, Wei CHEN, Amy Shaw-Ru CHEN, Edward Derrick PASCUA, Thomas John VAN BLARCOM, Leila Marie BOUSTANY, Weihsien HO, Yik Andy YEUNG, Pavel STROP, Arvind RAJPAL
  • Bicyclic-fused heteroaryl or aryl compounds
    Patent number: 9458168
    Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
    Type: Grant
    Filed: April 3, 2015
    Date of Patent: October 4, 2016
    Assignee: Pfizer Inc.
    Inventors: John David Trzupek, Katherine Lin Lee, Mark Edward Bunnage, Seungil Han, David Hepworth, Frank Eldridge Lovering, John Paul Mathias, Nikolaos Papaioannou, Joseph Walter Strohbach, Stephen Wayne Wright, Christoph Wolfgang Zapf, Lori Krim Gavrin, Arthur Lee, Kevin Joseph Curran, Christoph Martin Dehnhardt, Eddine Saiah, Joel Adam Goldberg, Xiaolun Wang, Richard Vargas, Michael Dennis Lowe, Akshay Patny
  • Apixaban solution formulations
    Patent number: 9452134
    Abstract: Apixaban liquid formulation is provided. Also provided is a method of administering an apixaban liquid formulation.
    Type: Grant
    Filed: September 26, 2013
    Date of Patent: September 27, 2016
    Assignees: Bristol-Myers Squibb Company, Pfizer Inc.
    Inventors: Sherif Ibrahim Farag Badawy, Susan Lum
  • Glucagon receptor modulators
    Patent number: 9452999
    Abstract: The present invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof wherein R1, R2, R3, A1, A2, A3, A4, L, B1, B2, B3 and B4 are as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon.
    Type: Grant
    Filed: June 4, 2015
    Date of Patent: September 27, 2016
    Assignee: Pfizer Inc.
    Inventors: Gary Erik Aspnes, Mary Theresa Didiuk, Kevin James Filipski, Angel Guzman-Perez, Esther Cheng Yin Lee, Jeffrey Allen Pfefferkorn, Benjamin Dawson Stevens, Meihua Mike Tu
  • BIFUNCTIONAL CYTOTOXIC AGENTS CONTAINING THE CTI PHARMACOPHORE
    Publication number: 20160271270
    Abstract: The present invention is directed to novel bifunctional CTI-CTI and CBI-CTI dimers of the formula: F1-L1-T-L2-F2 where F1, L1, T, L2 and F2 are as defined herein, useful for the treatment for proliferative diseases, where the inventive dimers can function as stand-alone drugs, payloads in antibody-drug-conjugates (ADCs), and linker-payload compounds useful in connection with the production or administration of such ADCs; and to compositions including the aforementioned dimers, linker-payloads and ADCs, and methods for using these dimers, linker-payloads and ADCs, to treat pathological conditions including cancer.
    Type: Application
    Filed: March 15, 2016
    Publication date: September 22, 2016
    Applicant: Pfizer Inc.
    Inventors: Andreas MADERNA, Chakrapani SUBRAMANYAM, Lawrence N. TUMEY, Zecheng CHEN, Jeffrey M. CASAVANT
  • HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF
    Publication number: 20160272625
    Abstract: The invention is directed to a class of compounds, including the pharmaceutically acceptable salts of the compounds, having the structure of formula I: as defined in the specification. The invention is also directed to compositions containing and uses of the compounds of formula I.
    Type: Application
    Filed: June 1, 2016
    Publication date: September 22, 2016
    Applicant: PFIZER INC.
    Inventors: ANTON FRANZ JOSEPH FLIRI, RANDALL JAMES GALLASCHUN, CHRISTOPHER JOHN O'DONNELL, JACOB BRADLEY SCHWARZ, BARBARA EILEEN SEGELSTEIN
  • Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
    Patent number: 9439902
    Abstract: Compounds of Formula (A) and (B) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by sodium-glucose transporter inhibitors (in particular, SGLT2 inhibitors).
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: September 13, 2016
    Assignee: Pfizer Inc.
    Inventor: Vincent Mascitti
  • Diacylglycerol acyltransferase 2 inhibitors
    Patent number: 9440949
    Abstract: Compounds of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.
    Type: Grant
    Filed: March 10, 2015
    Date of Patent: September 13, 2016
    Assignee: Pfizer Inc.
    Inventors: Shawn Cabral, Kentaro Futatsugi, David Hepworth, Kim Huard, Daniel Wei-Shung Kung, Suvi Tuula Marjukka Orr, Kun Song
  • Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
    Patent number: 9439901
    Abstract: Compounds of Formula (A) and (B) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by sodium-glucose transporter inhibitors (in particular, SGLT2 inhibitors).
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: September 13, 2016
    Assignee: Pfizer Inc.
    Inventor: Vincent Mascitti
  • Anti-Notch3 antibodies and antibody-drug conjugates
    Patent number: 9433687
    Abstract: The present invention provides for anti-Notch3 antibodies, anti-Notch3 antibody-drug conjugates and methods for preparing and using the same.
    Type: Grant
    Filed: November 6, 2013
    Date of Patent: September 6, 2016
    Assignee: Pfizer Inc.
    Inventors: Kenneth G. Geles, Yijie Gao, Puja Sapra, Lioudmila Gennadievna Tchistiakova, Bin-Bing Stephen Zhou
  • INTERMEDIATES AND METHODS FOR SYNTHESIZING CALICHEAMICIN DERIVATIVES
    Publication number: 20160251389
    Abstract: The present invention relates to intermediates of Formula I and to methods of synthesizing and purifying calicheamicin derivatives.
    Type: Application
    Filed: October 28, 2014
    Publication date: September 1, 2016
    Applicant: Pfizer Inc.
    Inventors: Robert Wayne Dugger, Leo Joseph Letendre, Vimalkumar Babubhai Patel, Amarnauth Shastrie Prashad, Chunchun Zhang
  • 2-amino-6-methyl-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl-1,3-thiazol-4-yl amides
    Patent number: 9428523
    Abstract: The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, and the variable R1 is as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
    Type: Grant
    Filed: February 9, 2016
    Date of Patent: August 30, 2016
    Assignee: Pfizer Inc.
    Inventors: Michael Aaron Brodney, Elizabeth Mary Beck, Christopher Ryan Butler, Lei Zhang, Brian Thomas O'Neill, Gabriela Barreiro, Erik Alphie LaChapelle, Bruce Nelsen Rogers
  • Tandem purification of proteins
    Patent number: 9428546
    Abstract: The present disclosure provides methods for purifying products from a fluid. In some embodiments, provided purification methods use a combination of purification modes (e.g., protein A and ion exchange) operated in tandem, wherein at least one of the modes utilizes weak partitioning. In some embodiments, provided purification methods operate under robust conditions in which a degree of binding between a product and resin is maintained despite variations in operating parameters.
    Type: Grant
    Filed: July 29, 2011
    Date of Patent: August 30, 2016
    Assignee: Pfizer Inc.
    Inventors: Jonathan Lee Coffman, Ranganathan Godavarti, Michael Shamashkin
  • Platelet-derived growth factor B specific antibodies and compositions and uses thereof
    Patent number: 9428577
    Abstract: The present invention provides antibodies, or antigen-binding fragment thereof, which specifically bind to PDGF-B. The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of PDGF-B mediated diseases, disorders or conditions.
    Type: Grant
    Filed: November 8, 2013
    Date of Patent: August 30, 2016
    Assignee: Pfizer Inc.
    Inventors: Robert Arch, Gregory Carven, Jun Kuai, Lydia Mosyak, Shinji Ogawa, Dirk Ponsel, Robert Rauchenberger
  • Process for annealing amorphous atorvastatin
    Patent number: 9428455
    Abstract: Processes for annealing amorphous atorvastatin is described. Pharmaceutical compositions and formulations containing annealed amorphous atorvastatin are also described.
    Type: Grant
    Filed: April 16, 2015
    Date of Patent: August 30, 2016
    Assignee: Pfizer Inc.
    Inventors: Renuka Devi Reddy, Evgenyi Shalaev, Ravi Mysore Shanker, Carl Bernard Ziegler
  • SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS
    Publication number: 20160244475
    Abstract: Compounds of the general formula (I): processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.
    Type: Application
    Filed: February 17, 2016
    Publication date: August 25, 2016
    Applicant: Pfizer Inc.
    Inventors: John Howard Tatlock, Indrawan James McAlpine, Michelle Bich Tran-Dube, Eugene Yuanjin Rui, Martin James Wythes, Robert Arnold Kumpf, Michele Ann McTigue
  • Anti-tofacitinib antibodies and uses thereof for drug monitoring
    Patent number: 9408922
    Abstract: The invention provides selective tofacitinib antibodies, immunogenic tofacitinib conjugates that are useful as immunogenic molecules for the generation of antibodies specific for tofacitinib, along with methods for measuring the concentration of tofacitinib in a sample, processes for making the antibodies, and assays and kits for using the antibodies.
    Type: Grant
    Filed: June 18, 2013
    Date of Patent: August 9, 2016
    Assignee: Pfizer Inc.
    Inventors: Joseph Paul Gardner, II, Victoria Yatsum Wong
  • Antibody to GDF8 and uses thereof
    Patent number: 9409981
    Abstract: The disclosure provides novel molecules related to growth and differentiation factor 8 (GDF8), in particular epitopes specific to GDF8 and other specific antagonists of GDF8 in particular anti GDF8 antibodies or antigen binding protein or fragment thereof which may inhibit GDF8 activity and signal in vitro and/or in vivo. The disclosure also provides for an immunoassay used to detect and quantitate GDF8. The disclosure also provides methods for diagnosing, preventing, ameliorating, and treating GDF8 associated disorders, e.g., degenerative orders of muscle, bone, and insulin metabolism. Finally, the disclosure provides pharmaceuticals for the treatment of such disorders by using the antibodies, polypeptides, polynucleotides, and vectors of the invention.
    Type: Grant
    Filed: March 8, 2013
    Date of Patent: August 9, 2016
    Assignee: Pfizer Inc.
    Inventors: Edward Roland LaVallie, Lisa Anne Collins-Racie, Christopher John Corcoran, Lioudmila Gennadievna Tchistiakova, John Adam Nowak, Riyez Karim, Xiang-Yang Tan, Kimberly Ann Marquette, Geertruida Machteld Veldman